[Clinical experience in the use of dormicum (midazolam) in anesthesiology and intensive care]

The authors analyze the efficacy of midazolam (dormicum, Egys, Hungary) used for induction anesthesia in 35 patients subjected to planned surgery for varicose disease of the lower limbs and on the abdominal organs and in 17 critical patients in intensive care units. To assess the hemodynamics, catheterization of the peripheral and pulmonary arteries was carried out, cardiac output, pressure in cardiac cavities, pulmonary capillary wedging pressure assessed, total peripheral and total pulmonary resistance, cardiac and stroke indexes estimated, gaseous composition of arterial and mixed venous blood analyzed. The drug had virtually no side effects on the function of vital systems of the body. Midazolam fully meets the requirements to drugs used for induction anesthesia and is compatible to such drugs as barbiturates, diazepam, ketamine. The drug can meet pharmacodynamic and pharmacokinetic requirements to sedative agents used in intensive care units, excepting analgesia. However, the need in analgesics and their doses are reduced during sedative therapy with midazolam. Midazolam effects on the lesser circulation hemodynamics permit its use as a sedative agent in patients with respiratory distress syndrome and pulmonary artery thromboembolism; it is also advisable for induction anesthesia in patients operated on for pulmonary artery thromboembolism and in other patients with lesser circulation hypertension.